CAS: 167465-36-3; (R)-1-(4-((1Ar,6R,10Bs)-1,1-Difluoro-1,1A,6,10B-Tetrahydrodibenzo[a,E]Cyclopropa[c][7]Annulen-6-yl)Piperazin-1-yl)-3-(Quinolin-5-Yloxy)Propan-2-Ol Trihydrochloride

上下游产品

5-[(2R)-oxiranylmethoxy]-quinoline

专利信息

专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人：PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人：CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

专利号:US-2025241876-A1
优先权日:2023-07-19
标 题:Anti-tumor compounds and methods of use thereof and synthesis thereof
发明人：QUAY STEVEN CARL
权利人:ATOSSA THERAPEUTICS INC
摘要:Described herein are pharmaceutical compounds and compositions and methods of making thereof. Methods of synthesis for the compounds are described herein. The compounds or compositions described herein may exhibit aromatase inhibition activity or estrogen receptor activity. The compounds and compositions described herein may be useful in the treatment of a condition in a subject.

专利号:US-2023192682-A1
优先权日:2019-11-14
标题:Improved synthesis of kras g12c inhibitor compound

专利号:US-2023192681-A1
优先权日:2019-11-14
标 题 :Improved synthesis of kras g12c inhibitor compound

专利号:US-2024279225-A1
优先权日:2021-04-08
标 题 :Compounds and methods for theranostic targeting of parp activity
发明人：PISANESCHI FEDERICA; MUZZIOLI RICCARDO; GAMMON SETH; PIWNICA-WORMS DAVID
权利人:UNIV TEXAS
摘要:The synthesis and use of radiolabeled derivatives of poly-(ADP-ribose) (PARP) inhibitors in positron emission tomography (PET) imaging methods are disclosed. A novel non-radioactive analogue of the PARP inhibitor Talazoparib (TZ) provides a branch point for the syntheses of various radiolabeled Talazoparib derivatives. Aspects of the disclosure include such radiolabeled derivatives and TZ analogues, along with methods of use for diagnosis, treatment, imaging, and theranosis of cancer.